Episode Details
Back to Episodes
Cannabis Reclassified to Schedule III: What This Means for Industry Growth and Investors
Published 4 days, 7 hours ago
Description
CANNABIS INDUSTRY ANALYSIS: FEDERAL RECLASSIFICATION REVERBERATES THROUGH MARKETS
The Trump administration has delivered a landmark shift in cannabis policy that sent shockwaves through the industry in the past 48 hours. Acting US Attorney General Todd Blanche signed an executive order reclassifying state-licensed medical marijuana from Schedule I to Schedule III, marking what industry observers describe as the most significant federal advancement in cannabis policy in decades.[1]
The reclassification represents a historic moment after President Trump signaled this direction last December. Schedule III status recognizes legitimate medical uses and reduces dangerous drug classification alongside heroin and LSD.[2] This change enables more targeted research into marijuana safety and efficacy while expanding patient access to treatments.[4]
Market reaction proved volatile and puzzling. Cannabis stocks initially surged in premarket trading but reversed sharply by afternoon. Curaleaf Holdings, the largest US cannabis company, dropped 24 percent. Other major operators also declined: Tilray Brands fell 11.82 percent, Green Thumb Industries tumbled 13.64 percent, and Trulieve Cannabis slid 3.93 percent. The AdvisorShares Pure US Cannabis ETF declined as much as 15 percent.[2][4] Analyst Aaron Grey from Alliance Global Partners attributed some confusion to the order's narrow application to medical use only, not recreational usage.[4]
For cannabis businesses, the practical benefits are substantial. Companies can now deduct ordinary business expenses like rent and employee salaries on taxes, addressing the burden of Section 280E of the Internal Revenue Code that previously prevented these deductions.[7] The reclassification also promises easier access to banking systems and more affordable insurance options, ending the cash-only operations that plague the $47 billion industry.[5][7]
Regulatory easing extends to research capabilities. Scientists have long argued that Schedule I classification hampers clinical studies into cannabis treatments for chronic pain, epilepsy, and anxiety disorders.[7] Schedule III status removes these restrictions while enabling FDA-approved research pathways.
Industry leaders welcomed the policy shift despite initial stock volatility. Colorado cannabis sector representatives expressed cautious optimism with a wait-and-see approach.[9] The key question now centers on implementation details and whether this federal change will translate into the predicted financial and operational improvements for cannabis companies navigating state-by-state regulations.
For great deals today, check out https://amzn.to/44ci4hQ
This content was created in partnership and with the help of Artificial Intelligence AI
The Trump administration has delivered a landmark shift in cannabis policy that sent shockwaves through the industry in the past 48 hours. Acting US Attorney General Todd Blanche signed an executive order reclassifying state-licensed medical marijuana from Schedule I to Schedule III, marking what industry observers describe as the most significant federal advancement in cannabis policy in decades.[1]
The reclassification represents a historic moment after President Trump signaled this direction last December. Schedule III status recognizes legitimate medical uses and reduces dangerous drug classification alongside heroin and LSD.[2] This change enables more targeted research into marijuana safety and efficacy while expanding patient access to treatments.[4]
Market reaction proved volatile and puzzling. Cannabis stocks initially surged in premarket trading but reversed sharply by afternoon. Curaleaf Holdings, the largest US cannabis company, dropped 24 percent. Other major operators also declined: Tilray Brands fell 11.82 percent, Green Thumb Industries tumbled 13.64 percent, and Trulieve Cannabis slid 3.93 percent. The AdvisorShares Pure US Cannabis ETF declined as much as 15 percent.[2][4] Analyst Aaron Grey from Alliance Global Partners attributed some confusion to the order's narrow application to medical use only, not recreational usage.[4]
For cannabis businesses, the practical benefits are substantial. Companies can now deduct ordinary business expenses like rent and employee salaries on taxes, addressing the burden of Section 280E of the Internal Revenue Code that previously prevented these deductions.[7] The reclassification also promises easier access to banking systems and more affordable insurance options, ending the cash-only operations that plague the $47 billion industry.[5][7]
Regulatory easing extends to research capabilities. Scientists have long argued that Schedule I classification hampers clinical studies into cannabis treatments for chronic pain, epilepsy, and anxiety disorders.[7] Schedule III status removes these restrictions while enabling FDA-approved research pathways.
Industry leaders welcomed the policy shift despite initial stock volatility. Colorado cannabis sector representatives expressed cautious optimism with a wait-and-see approach.[9] The key question now centers on implementation details and whether this federal change will translate into the predicted financial and operational improvements for cannabis companies navigating state-by-state regulations.
For great deals today, check out https://amzn.to/44ci4hQ
This content was created in partnership and with the help of Artificial Intelligence AI